Opening Address & Keynote Presentation by Ablexis and AlivaMab Biologics. Driven by Diversity: AlivaMab' Platforms Fuel Biologics Discovery for Complex Targets
17 Jun 2024
Salon H
Target Selection
Lead Identification & Optimization
Formats & Scaffolds
Bi/Multispecifics
Emerging Technologies
){kind=logo}
Successful biologics development hinges on innovative strategies for generating diversity in antibody discovery. With an ever-growing suite of AlivaMab® Mouse strains and creative ‘fit-for-purpose’ strategies, Ablexis and AlivaMab Biologics are delivering diverse panels of lead-quality antibodies. Here, we will highlight how diverse AlivaMab Mouse strains and discovery processes enable successful discovery of diverse panels for CLC, human single-domain, membrane multispanners, CD3, and TCRm antibodies.
